Exact Sciences Corporation Surges to 209th Most Traded Stock Despite 2.33% Price Decline

On May 30, 2025, Exact Sciences Corporation (EXAS) experienced a significant surge in trading volume, with a turnover of 7.64 billion, marking a 458.6% increase from the previous day. This substantial rise in trading activity positioned EXAS as the 209th most traded stock for the day. However, despite the high trading volume, the stock price of EXAS declined by 2.33%, marking the second consecutive day of decline and a total decrease of 3.10% over the past two days.

On May 28, 2025, Exact Sciences announced the expansion of clinical validation for its Oncodetect™ test and outlined its innovation roadmap for molecular residual disease. This development is part of the company's ongoing efforts to enhance its diagnostic capabilities and improve patient outcomes through early cancer detection and precision oncology.

Exact Sciences Corporation is a leading global company in advanced cancer diagnostics, offering a range of products for earlier cancer detection and treatment guidance. The company's portfolio includes the Cologuard test, a non-invasive, stool-based DNA screening test for colorectal cancer, and the Oncotype DX series of tests, which provide personalized treatment guidance for breast and colon cancer patients. The company's focus on research and development in colorectal cancer screening, multi-cancer early detection (MCED) tests, and molecular residual disease (MRD) tests positions it at the forefront of cancer diagnostics innovation.